Is serologic reactivity of unidentified specificity (SRUS) associated with hemolytic disease of the fetus and newborn (HDFN)?

HDFN can result in significant morbidity and mortality. While SRUS is generally thought to be clinically insignificant in pregnancy, there is only one single center experience published to support this belief. Therefore, SRUS still poses a management dilemma for both hospital transfusion services and obstetricians. The objective of this study is to collect data from multiple centers to determine the significance of SRUS with regard to associated risk of HDFN requiring intervention.

Completed

159

CTS

Yazer, Lu